ROKIT Healthcare Inc.
Financials
Valuation Metrics
ROKIT Healthcare Inc.'s Market Cap is ₩4859B. At end of 2025 it was ₩1.1T. Ranked #492 of 2,419 in KR market (top 20%), #190 of 1,638 on KOSDAQ (top 12%), #54 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 23%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 485.85B KRW | KR#492/2,419 Sec#54/231 |
| Revenue | 32.81B KRW | KR#1,999/2,419 Sec#138/231 |
| Net Income | -12.69B KRW | KR—/2,419 Sec—/231 |
| Total Assets | 108.22B KRW | KR#1,714/2,419 Sec#134/231 |
| Net Assets | 6.72B KRW | KR#2,387/2,419 Sec#227/231 |
| Employees | 86 | KR#1,757/2,419 Sec#140/231 |
| Value | ||
| P/B | 72.28x | KR#2,414/2,419 Sec#231/231 |
| P/S | 14.81x | KR#2,306/2,419 Sec#173/231 |
| FCF Yield | -3.58% | KR—/2,419 Sec—/231 |
| Profitability | ||
| ROE | -188.81% | KR#2,376/2,419 Sec#224/231 |
| ROA | -11.73% | KR#2,137/2,419 Sec#162/231 |
| Op. Margin | -46.10% | KR#2,224/2,419 Sec#160/231 |
| Revenue Growth | 106.19% | KR#79/2,419 Sec#15/231 |
| Financial Health | ||
| Debt Ratio | 1509.90% | KR#2,389/2,419 Sec#228/231 |
| Total Debt | 25.05B KRW | KR#1,304/2,419 Sec#102/231 |
| FCF | -17.39B KRW | KR#1,858/2,419 Sec#176/231 |
| Cash | 20.18B KRW | KR#1,248/2,419 Sec#91/231 |
| Current Ratio | 0.89x | KR#1,847/2,419 Sec#178/231 |
| Performance | ||
| 1Y Return | 3.15% | KR#1,003/2,419 Sec#64/231 |
| 1M Return | 2.96% | KR#920/2,419 Sec#89/231 |
| From 52W High | -81.89% | KR#2,358/2,419 Sec#224/231 |
| 1Y MDD | -83.37% | KR#2,340/2,419 Sec#220/231 |
| Trading | ||
| Volume | 102,086 shares | KR#804/2,419 Sec#93/231 |
| Trading Value | 2.94B KRW | KR#486/2,419 Sec#62/231 |
| Foreign Own. | 5.72% | KR#762/2,419 Sec#70/231 |
| Per Share | ||
| EPS | -728 KRW | KR—/2,419 Sec—/231 |
| BPS | 385 KRW | KR#2,396/2,419 Sec#227/231 |
Company Info
Rokit Healthcare, established in 2012, leads the innovative regenerative medicine market. The company has commercialized AI ultra-precision patient-specific organ and skin regeneration platforms, built upon four core technologies including AI for medical lesion modeling and disposable regeneration kits. It provides an economical treatment method for chronic diseases, achieving 90% regeneration with a single procedure, and is expanding its application to cartilage and kidney regeneration platforms. Rokit Healthcare is headquartered in Geumcheon-gu, Seoul Metropolitan City.